- Home
- CNTY vs TIL Comparison
CNTY vs TIL Comparison
Compare CNTY & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTY | TIL |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 53.1M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNTY | TIL |
|---|---|---|
| Price | $1.24 | $7.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.00 | ★ $125.00 |
| AVG Volume (30 Days) | ★ 68.4K | 6.2K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.31 | 6.06 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $430,529,000.00 | N/A |
| Revenue This Year | $7.17 | N/A |
| Revenue Next Year | $3.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.82 | N/A |
| 52 Week Low | $1.14 | $5.67 |
| 52 Week High | $2.80 | $33.83 |
Technical Indicators
Market Signals| Indicator | CNTY | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 52.08 | 64.15 |
| Support Level | $1.24 | $7.67 |
| Resistance Level | $1.34 | $8.04 |
| Average True Range (ATR) | 0.04 | 0.21 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 48.07 | 95.24 |
Price Performance
Historical ComparisonAbout CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has five reportable segments based on the geographical locations in which its casinos operate; US East, US Midwest, US West, Canada, and Poland.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.